Literature DB >> 32640891

Dysregulation of the OGF-OGFr pathway correlates with elevated serum OGF and ocular surface complications in the diabetic rat.

Ian S Zagon1, Joseph W Sassani2, Indira Purushothaman1, Patricia J McLaughlin1.   

Abstract

IMPACT STATEMENT: This research extends our knowledge about the presence and role of the OGF-OGFr regulatory axis in type 1 diabetes (T1D) and demonstrates specific targets within the pathway that are dysregulated. Serum levels of OGF, an inhibitory growth factor, are significantly elevated in male T1D rats, and OGFr serum values are increased in T1D. The onset of elevated OGF corresponds to the onset of ocular surface complications including dry eye, delayed corneal epithelial repair, and abnormal corneal surface sensitivity in T1D. Systemic insulin does not protect against elevated OGF levels or the onset of dry eye and sensitivity. These data are the first to associate some ocular surface defects in T1D with alterations in the OGF-OGFr pathway.

Entities:  

Keywords:  Hyperglycemia; corneal surface sensitivity; delayed corneal epithelialization; dry eye; serum OGF; serum OGFr

Year:  2020        PMID: 32640891      PMCID: PMC7441350          DOI: 10.1177/1535370220940273

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  26 in total

1.  Plasma met-enkephalin in type I diabetes.

Authors:  M Negri; G Tonnarini; M D'Alessandro; F Fallucca
Journal:  Metabolism       Date:  1992-05       Impact factor: 8.694

Review 2.  Effects of diabetes on the eye.

Authors:  Gerard A Lutty
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-12-13       Impact factor: 4.799

3.  Regulation of corneal repair by particle-mediated gene transfer of opioid growth factor receptor complementary DNA.

Authors:  Ian S Zagon; Joseph W Sassani; Kristin J Malefyt; Patricia J McLaughlin
Journal:  Arch Ophthalmol       Date:  2006-11

Review 4.  The biology of the opioid growth factor receptor (OGFr).

Authors:  Ian S Zagon; Michael F Verderame; Patricia J McLaughlin
Journal:  Brain Res Brain Res Rev       Date:  2002-02

5.  Corneal safety of topically applied naltrexone.

Authors:  Ian S Zagon; Matthew S Klocek; Joseph W Sassani; David T Mauger; Patricia J McLaughlin
Journal:  J Ocul Pharmacol Ther       Date:  2006-10       Impact factor: 2.671

6.  Dry eye reversal and corneal sensation restoration with topical naltrexone in diabetes mellitus.

Authors:  Ian S Zagon; Matthew S Klocek; Joseph W Sassani; Patricia J McLaughlin
Journal:  Arch Ophthalmol       Date:  2009-11

7.  Naltrexone and insulin are independently effective but not additive in accelerating corneal epithelial healing in type I diabetic rats.

Authors:  Matthew S Klocek; Joseph W Sassani; Patricia J McLaughlin; Ian S Zagon
Journal:  Exp Eye Res       Date:  2009-07-01       Impact factor: 3.467

8.  Conserved expression of the opioid growth factor, [Met5]enkephalin, and the zeta (zeta) opioid receptor in vertebrate cornea.

Authors:  I S Zagon; J W Sassani; G Allison; P J McLaughlin
Journal:  Brain Res       Date:  1995-02-06       Impact factor: 3.252

9.  Naltrexone, an opioid antagonist, facilitates reepithelialization of the cornea in diabetic rat.

Authors:  Ian S Zagon; Joe B Jenkins; Joseph W Sassani; James D Wylie; Torre B Ruth; Jamie L Fry; C Max Lang; Patricia J McLaughlin
Journal:  Diabetes       Date:  2002-10       Impact factor: 9.461

10.  Efficacy and safety of a novel naltrexone treatment for dry eye in type 1 diabetes.

Authors:  Patricia J McLaughlin; Joseph W Sassani; Michelle B Titunick; Ian S Zagon
Journal:  BMC Ophthalmol       Date:  2019-01-28       Impact factor: 2.209

View more
  6 in total

1.  Dysregulation of the OGF-OGFr pathway and associated diabetic complications.

Authors:  Patricia J McLaughlin; Joseph W Sassani; Ian S Zagon
Journal:  J Diabetes Clin Res       Date:  2021

2.  Ocular surface complications result from dysregulation of the OGF-OGFr signaling pathway in female diabetic rats.

Authors:  Indira Purushothaman; Ian S Zagon; Joseph W Sassani; Patricia J Mclaughlin
Journal:  Exp Ther Med       Date:  2021-04-28       Impact factor: 2.447

3.  Sex differences in the magnitude of diabetic ocular surface complications: Role of serum OGF.

Authors:  Indira Purushothaman; Ian S Zagon; Joseph W Sassani; Shouhao Zhou; Patricia J McLaughlin
Journal:  Physiol Behav       Date:  2021-04-25

Review 4.  Opioids and Ocular Surface Pathology: A Literature Review of New Treatments Horizons.

Authors:  Celia García-López; Carmen Gómez-Huertas; José-María Sánchez-González; Davide Borroni; Marina Rodríguez-Calvo-de-Mora; Vito Romano; Rahul Rachwani-Anil; Juan-Francisco Ramos-López; Santiago Ortiz-Pérez; Carlos Rocha-de-Lossada
Journal:  J Clin Med       Date:  2022-03-04       Impact factor: 4.241

5.  Blockade of OGFr delays the onset and reduces the severity of diabetic ocular surface complications.

Authors:  Ian S Zagon; Joseph W Sassani; Indira Purushothaman; Patricia J McLaughlin
Journal:  Exp Biol Med (Maywood)       Date:  2020-11-17

Review 6.  Ocular surface complications in diabetes: The interrelationship between insulin and enkephalin.

Authors:  Indira Purushothaman; Ian S Zagon; Joseph W Sassani; Patricia J McLaughlin
Journal:  Biochem Pharmacol       Date:  2021-07-26       Impact factor: 6.100

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.